Skip to main content

Advertisement

Table 1 Baseline characteristics of the study sample

From: Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment

  All (n = 258) Stable MCI (n = 119) Progressive MCI (n = 139) p valuec
Age, years 74.1 (69.5–78.5) 74.4 (69.1–78.2) 73.6 (69.8–78.7) > 0.999
Female, n (%) 101 (39.1) 40 (33.6) 61 (43.9) 0.119
Education, years 16 (14–18) 16 (14–18) 16 (14–18) 0.469
APOE ε4 carrier, n (%) 176 (68.2) 78 (65.6) 98 (70.5) 0.473
Cognition
 MMSE 27 (25–29) 28 (26–29) 26 (25–28) < 0.001
 CDR SB 1.5 (1.0–2.5) 1.5 (1.0–2.0) 2.0 (1.0–2.5) < 0.001
 ADAS-cog 11 11.8 (9.0–15.7) 10.7 (7.2–13.2) 13.0 (10.8–16.2) < 0.001
CSF markers
 Aβ1–42, mean ± SD, pg/mL 136.1 ± 25.7 136.7 ± 27.2 133.7 ± 25.0 0.345
 CSF t-tau, pg/mLa 104.0 (77.0–148.5) 91.0 (68.0–133.0) 113.0 (84.0–153.0) 0.006
 CSF p-tau, pg/mLb 41.0 (31.0–58.0) 37.0 (27.0–51.0) 45.0 (36.0–64.0) < 0.001
MRI
 Tesla, n (%)     0.714
  1.5 143 (55.4) 64 (53.8) 79 (56.8)  
  3.0 115 (44.6) 55 (46.2) 60 (43.2)
 MTA, n (%) 123 (47.7) 47 (39.5) 76 (54.7) 0.021
 PA, n (%) 174 (67.4) 65 (54.6) 109 (78.4) <0.001
 Atrophy pattern, n (%)     <0.001
  No atrophy 51 (19.8) 39 (32.8) 12 (8.6)  
  MTA only 33 (12.8) 15 (12.6) 18 (13.0)
  PA only 84 (32.6) 33 (27.7) 51 (36.7)
  Both MTA and PA 90 (34.9) 32 (26.9) 58 (41.7)
  1. Data are presented as the median (interquartile range) unless otherwise specified
  2. a Data for 7 subjects were not available
  3. b Data for 1 subject were not available
  4. c Stable MCI vs. progressive MCI
  5. β-amyloid, ADAS-cog Alzheimer’s Disease Assessment Scale-cognitive subscale, CDR SB Clinical Dementia Rating Sum of Boxes, CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini-Mental State Examination, MRI magnetic resonance imaging, MTA medial temporal lobe atrophy, PA posterior atrophy, p-tau tau phosphorylated at threonine 181, SD standard deviation, t-tau total tau